639
Views
19
CrossRef citations to date
0
Altmetric
Drug Profile

The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia

, , , , &

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Raquel Vinhas, Alexandra Lourenço, Susana Santos, Marcos Lemos, Patrícia Ribeiro, Aida Botelho de Sousa, Pedro Viana Baptista & Alexandra Ramos Fernandes. (2018) A novel BCR-ABL1 mutation in a patient with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia. OncoTargets and Therapy 11, pages 8589-8598.
Read now
Masahiko Sumi, Keijiro Sato, Hiroko Kaiume, Wataru Takeda, Takehiko Kirihara, Toshimitsu Ueki, Yuki Hiroshima & Hikaru Kobayashi. (2017) Second cord blood transplantation and interferon-α maintenance therapy for relapsed Ph+ acute lymphoblastic leukemia with the T315I mutation. Leukemia & Lymphoma 58:8, pages 2005-2007.
Read now

Articles from other publishers (17)

Yue Cao, Peng Xu, Yangling Shen, Wei Wu, Min Chen, Fei Wang, Yuandong Zhu, Feng Yan, Weiying Gu & Yan Lin. (2023) Exosomes and cancer immunotherapy: A review of recent cancer research. Frontiers in Oncology 12.
Crossref
Jorge Cortes, Carolina Pavlovsky & Susanne Saußele. (2021) Chronic myeloid leukaemia. The Lancet 398:10314, pages 1914-1926.
Crossref
Yongfeng Chen, Jing Li & Zhiqiang Zhao. (2021) Redox Control in Acute Lymphoblastic Leukemia: From Physiology to Pathology and Therapeutic Opportunities. Cells 10:5, pages 1218.
Crossref
Wendy Stock, Giovanni Martinelli, Matthias Stelljes, Daniel J. DeAngelo, Nicola Gökbuget, Anjali S. Advani, Susan O’Brien, Michaela Liedtke, Akil A. Merchant, Ryan D. Cassaday, Tao Wang, Hui Zhang, Erik Vandendries, Elias Jabbour, David I. Marks & Hagop M. Kantarjian. (2020) Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome–positive relapsed/refractory acute lymphoblastic leukemia. Cancer 127:6, pages 905-913.
Crossref
Wasithep Limvorapitak, Weerapat Owattanapanich, Eakkapol Utchariyaprasit, Pimjai Niparuck, Teeraya Puavilai, Adisak Tantiworawit, Thanawat Rattanathammethee, Supawee Saengboon, Chantarapa Sriswasdi, Jakrawadee Julamanee, Piroon Saelue, Chantana Polprasert, Kitsada Wudhikarn, Chinadol Wanitpongpun & Kannadit Prayongratana. (2019) Better survivals in adolescent and Young adults, compared to adults with acute lymphoblastic leukemia – A multicenter prospective registry in Thai population. Leukemia Research 87, pages 106235.
Crossref
Kyoko Masuda, Tomonori Nakazato, Yuriko Nishiyama‐Fujita, Chisako Ito, Shinji Ogura, Kota Mizuno, Takahiro Kamiya, Yoshinobu Aisa & Takehiko Mori. (2019) Successful treatment with ponatinib for central nervous system relapse of Philadelphia chromosome‐positive B‐cell acute lymphoblastic leukaemia. Internal Medicine Journal 49:10, pages 1332-1334.
Crossref
Anjana Joel, Prasanth Ganesan, Krishnarathnam Kannan, Venkatraman Radhakrishnan, Trivadi S Ganesan & Tenali Gnana Sagar. (2021) T315I Mutation in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia: Role for Detection of Mutations. Indian Journal of Medical and Paediatric Oncology 39:03, pages 417-418.
Crossref
Matthieu Lewis, Mhairi Copland, Simona Soverini, Irina Sadovnik, Aurélie Bedel, Stéphane Prost, Antoine Italiano & François-Xavier Mahon. (2017) What are the challenges in 2016 regarding resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and cancer?. Hematological Oncology 35:4, pages 420-423.
Crossref
Maria Ilaria Del Principe, Domenico Del Principe & Adriano Venditti. (2017) Thrombosis in adult patients with acute leukemia. Current Opinion in Oncology 29:6, pages 448-454.
Crossref
Gabriele Stefanzl, Daniela Berger, Sabine Cerny-Reiterer, Katharina Blatt, Gregor Eisenwort, Wolfgang R. Sperr, Gregor Hoermann, Karin Lind, Alexander W. Hauswirth, Peter Bettelheim, Heinz Sill, Junia V. Melo, Ulrich Jäger & Peter Valent. (2017) The pan-BCL-2-blocker obatoclax (GX15-070) and the PI3-kinase/mTOR-inhibitor BEZ235 produce cooperative growth-inhibitory effects in ALL cells. Oncotarget 8:40, pages 67709-67722.
Crossref
Jasmine Noetzli, Mathilde Gavillet, Stavroula Masouridi-Levrat, Michel Duchosal & Olivier Spertini. (2017) T315I clone selection in a Ph+ all patient under low-dose ponatinib maintenance. Clinical Case Reports 5:8, pages 1320-1322.
Crossref
Takahiro Yoshida, Ei Leen Liew, Mihoko Ota, Hiroshi Nakayama, Yasuo Yanagihara, Yuki Nakamura, Taku Seriu & Masaru Kamishohara. (2017) Pharmacological characteristics and clinical outcomes of ponatinib (Iclusig<sup>®</sup>), a third-generation tyrosine kinase inhibitor. Folia Pharmacologica Japonica 150:1, pages 54-61.
Crossref
Annamaria Petrungaro, Massimo Gentile, Carla Mazzone, Rosa Greco, Giuseppina Uccello, Anna Grazia Recchia, Laura De Stefano, Sabrina Bossio, Angela Palummo, Rosellina Morelli, Caterina Musolino, Fortunato Morabito & Ernesto Vigna. (2017) Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant. Chemotherapy 62:6, pages 353-356.
Crossref
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors 481 504 .
Farhad RavandiMegan OthusSusan M. O'BrienStephen J. FormanChul S. HaJeffrey Y. C. WongMartin S. TallmanElisabeth PaiettaJanis RacevskisGeoffrey L. UyMary HorowitzNaoko TakebeRichard LittleUma BoratePartow KebriaeiLaura KingsburyHagop M. KantarjianJerald P. RadichHarry P. Erba & Frederick R. Appelbaum. (2016) US intergroup study of chemotherapy plus dasatinib and allogeneic stem cell transplant in Philadelphia chromosome positive ALL. Blood Advances 1:3, pages 250-259.
Crossref
Kirsten Bleckmann & Martin Schrappe. (2016) Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence. British Journal of Haematology 172:6, pages 855-869.
Crossref
Ewa Marcinkowska & Elżbieta Gocek. 2016. Resistance to Tyrosine Kinase Inhibitors. Resistance to Tyrosine Kinase Inhibitors 1 25 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.